Hepion Pharmaceuticals, Inc. (HEPA)
NASDAQ: HEPA · Real-Time Price · USD
0.694
+0.024 (3.63%)
Nov 20, 2024, 4:00 PM EST - Market closed
Hepion Pharmaceuticals Employees
Hepion Pharmaceuticals had 22 employees as of December 31, 2023. The number of employees decreased by 3 or -12.00% compared to the previous year.
Employees
22
Change (1Y)
-3
Growth (1Y)
-12.00%
Revenue / Employee
n/a
Profits / Employee
-$1,032,027
Market Cap
4.03M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Biofrontera | 85 |
Genetic Technologies | 55 |
Predictive Oncology | 35 |
Genprex | 26 |
Sonoma Pharmaceuticals | 10 |
Pasithea Therapeutics | 8 |
Chromocell Therapeutics | 8 |
Silo Pharma | 3 |
HEPA News
- 2 months ago - Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger - GlobeNewsWire
- 4 months ago - Fatty-Liver Focused Hepion Pharmaceuticals Agrees To Merge With Israel-Based Parkinson's Disease Drug Developer - Benzinga
- 7 months ago - Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH' Trial - GlobeNewsWire
- 9 months ago - Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell - GlobeNewsWire
- 9 months ago - Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds - GlobeNewsWire
- 11 months ago - Hepion Pharmaceuticals to Present at NASH-TAG 2024 - GlobeNewsWire
- 1 year ago - Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes - GlobeNewsWire
- 1 year ago - Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit - GlobeNewsWire